Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Comorbid Allergic Contact Dermatitis in Atopic Children
Description
The discussion focuses on the relationship between allergic contact dermatitis (ACD) and atopic dermatitis (AD) in children, emphasizing that these two conditions can coexist and that children with AD are at an increased risk of developing ACD. The speaker argues against the misconception that ACD cannot occur in children, pointing out that children exhibit similar rates of ACD as adults when sufficiently exposed to allergens. Various studies reveal that children with AD may have a longer duration of dermatitis and are more likely to have positive patch test results, indicating a higher prevalence of ACD. Key allergens identified in this population include common substances found in personal care products, such as methylisothiazolinone and propylene glycol, which are also relevant in treatments used for AD. The speaker highlights the importance of patch testing for children with AD to detect any underlying ACD contributing to their symptoms. Furthermore, there are considerations regarding the impact of newer immunomodulatory treatments like dupilumab, which, while effective for AD, may not adequately address coexisting ACD. Ultimately, the speaker stresses the need for clinicians to be vigilant in assessing the interplay between AD and ACD and the importance of targeted treatment strategies based on thorough patch testing.
View moreConclusions
- Atopic Dermatitis (AD) and Allergic Contact Dermatitis (ACD) can coexist in children.
- The prevalence of ACD is similar in both children and adults, despite misconceptions about children's exposure levels.
- Children with AD have a significantly higher prevalence of contact allergies compared to adults without AD.
- 20% of children with AD may also have ACD, which is often overlooked due to challenges in patch testing.
- Patients with more severe AD are more likely to have positive patch test results for contact allergens.
- Patch testing is crucial for diagnosing ACD in children with AD, providing clarity on treatment options.
- Common allergens in children with AD include nickel, fragrance mixes, and preservatives like cocamidopropyl betaine and propylene glycol.
- Careful consideration of personal care products and medications is necessary in managing AD to avoid allergen exposure.
- Dupilumab treatment may impact the presentation of ACD, highlighting the need for ongoing allergen testing in these patients.
- Kohli N, Nedorost S. Inflamed skin predisposes to sensitization to less potent allergens. J Am Acad Dermatol. 2016 Aug;75(2):312-317.e1. doi: 10.1016/j.jaad.2016.03.010. Epub 2016 Jun 8. PMID: 27287247.
- Malajian D, Belsito DV. Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis. J Am Acad Dermatol. 2013 Aug;69(2):232-7. doi: 10.1016/j.jaad.2013.03.012. Epub 2013 Apr 11. PMID: 23583066.
- Tam I, Yu J. Allergic Contact Dermatitis in Children: Recommendations for Patch Testing. Curr Allergy Asthma Rep. 2020 Jun 16;20(9):41. doi: 10.1007/s.... PMID: 32548648.
- Johnson H, Aquino MR, Snyder A, Collis RW, Franca K, Goldenberg A, Sui JY, Eichenfield DZ, Kozy BJ, Chen JK, Shope C, Goldminz AM, Yu J. Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: A multicenter retrospective case-control study. J Am Acad Dermatol. 2023 Jul 29:S0190-9622(23)01270-7. doi: 10.1016/j.jaad.2023.06.048. Epub ahead of print. PMID: 37768237.
- Reeder MJ, Warshaw E, Aravamuthan S, Belsito DV, Geier J, Wilkinson M, Atwater AR, White IR, Silverberg JI, Taylor JS, Fowler JF Jr, Maibach HI, Dekoven JG, Buhl T, Botto N, Giménez-Arnau AM, Gallo R, Mowad C, Lang CCV, DeLeo VA, Johnston G, Pratt MD, Brockow K, Adler BL, Houle MC, Dickel H, Schuttelaar MLA, Yu J, Spiewak R, Dunnick C, Filon FL, Valiukeviciene S, Uter W. Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe. JAM
- Ashbaugh AG, Murase EM, Raffi J, Botto N, Murase JE. Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing. Dermatitis. 2022 Jan-Feb 01;33(1):51-61. doi: 10.1097/DER.0000000000000801. PMID: 35029349.